<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<!-- saved from url=(0052)http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/ -->
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
        <!-- AppResources meta begin -->
        <script type="text/javascript">var ncbi_startTime = new Date();</script>
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="">

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="pmc"><meta name="ncbi_pdid" content="article"><meta name="ncbi_acc" content=""><meta name="ncbi_domain" content="brjclinpharm"><meta name="ncbi_report" content="record"><meta name="ncbi_type" content="fulltext"><meta name="ncbi_objectid" content=""><meta name="ncbi_pcid" content="/articles/PMC3162661/"><meta name="ncbi_app" content="pmc">
        <!-- Logger end -->
        
        <title>Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="./PMC3162661_files/jig.min.css"><script type="text/javascript" src="./PMC3162661_files/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE"><link rel="canonical" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/"><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="British Journal of Clinical Pharmacology"><meta name="citation_title" content="Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers"><meta name="citation_authors" content="Alicia J Allred, Carolyn J Bowen, Jung Wook Park, Bin Peng, Daphne D Williams, Mary Beth Wire, Edmund Lee"><meta name="citation_date" content="August 2011"><meta name="citation_issue" content="2"><meta name="citation_volume" content="72"><meta name="citation_firstpage" content="321"><meta name="citation_doi" content="10.1111/j.1365-2125.2011.03972.x"><meta name="citation_abstract_html_url" content="/pmc/articles/PMC3162661/?report=abstract"><meta name="citation_pmid" content="21434975"><meta name="DC.Title" content="Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers"><meta name="DC.Type" content="Text"><meta name="DC.Publisher" content="Wiley-Blackwell"><meta name="DC.Contributor" content="Alicia J Allred"><meta name="DC.Contributor" content="Carolyn J Bowen"><meta name="DC.Contributor" content="Jung Wook Park"><meta name="DC.Contributor" content="Bin Peng"><meta name="DC.Contributor" content="Daphne D Williams"><meta name="DC.Contributor" content="Mary Beth Wire"><meta name="DC.Contributor" content="Edmund Lee"><meta name="DC.Date" content="2011 Aug"><meta name="DC.Identifier" content="10.1111/j.1365-2125.2011.03972.x"><meta name="DC.Language" content="en"><meta property="og:title" content="Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers"><meta property="og:type" content="article"><meta property="og:description" content="Eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, inhibits the organic anion transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP) in vitro. OATP1B1 is important for hepatic uptake of rosuvastatin and inhibition ..."><meta property="og:url" content="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/"><meta property="og:site_name" content="PubMed Central (PMC)"><meta property="og:image" content="http://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@ncbi"><link rel="stylesheet" href="./PMC3162661_files/pmc.min.css" type="text/css"><link rel="stylesheet" href="./PMC3162661_files/pmc_extras_prnt.min.css" type="text/css" media="print"><script type="text/javascript" src="./PMC3162661_files/common.min.js">//</script><script type="text/javascript" src="./PMC3162661_files/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:&#39;/pmc/utils/ctxp/&#39;"><script type="text/javascript" src="./PMC3162661_files/jquery.citationexporter.js">//</script><link rel="stylesheet" href="./PMC3162661_files/citationexporter.css" type="text/css"><script type="text/javascript" src="./PMC3162661_files/MathJax.js"></script><script type="text/javascript" src="./PMC3162661_files/large-obj-scrollbars.min.js"></script><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-brjclinpharm.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">
        div.pmc_para_cit li.highlight,
        div.pmc_para_cit li.highlight .one_line_source
        { background: #E0E0E0; }
        a.bibr.highlight { background: #E0E0E0; } 
      </style><link rel="alternate" type="application/epub+zip" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/epub/"><link rel="alternate" type="application/pdf" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/pdf/bcp0072-0321.pdf">

        <!-- Page meta end -->
    <link rel="shortcut icon" href="http://www.ncbi.nlm.nih.gov/favicon.ico"><meta name="ncbi_phid" content="8A1A7CD776C27C210000000000897B4A"><link type="text/css" rel="stylesheet" href="./PMC3162661_files/3855312.css"><link type="text/css" rel="stylesheet" href="./PMC3162661_files/3929378.css" media="print"><style type="text/css" media="print">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }.print-log li { list-style-image: url('http://www.ncbi.nlm.nih.gov/stat?jsevent=print&ncbi_app=pmc&ncbi_db=pmc&ncbi_pcid=%2Farticles%2FPMC3162661%2F&ncbi_pdid=article&ncbi_phid=8A1A7CD776C27C210000000000897B4A'); }</style><style type="text/css">.print-log { position:absolute;left:-10000px;top:auto;width:1px;height:1px;overflow:hidden; }</style><style type="text/css">.MathJax_Preview {color: #888}
#MathJax_Message {position: fixed; left: 1em; bottom: 1.5em; background-color: #E6E6E6; border: 1px solid #959595; margin: 0px; padding: 2px 8px; z-index: 102; color: black; font-size: 80%; width: auto; white-space: nowrap}
#MathJax_MSIE_Frame {position: absolute; top: 0; left: 0; width: 0px; z-index: 101; border: 0px; margin: 0px; padding: 0px}
.MathJax_Error {color: #CC0000; font-style: italic}
</style><style type="text/css">.MathJax_Hover_Frame {border-radius: .25em; -webkit-border-radius: .25em; -moz-border-radius: .25em; -khtml-border-radius: .25em; box-shadow: 0px 0px 15px #83A; -webkit-box-shadow: 0px 0px 15px #83A; -moz-box-shadow: 0px 0px 15px #83A; -khtml-box-shadow: 0px 0px 15px #83A; border: 1px solid #A6D ! important; display: inline-block; position: absolute}
.MathJax_Menu_Button .MathJax_Hover_Arrow {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 4px; -webkit-border-radius: 4px; -moz-border-radius: 4px; -khtml-border-radius: 4px; font-family: 'Courier New',Courier; font-size: 9px; color: #F0F0F0}
.MathJax_Menu_Button .MathJax_Hover_Arrow span {display: block; background-color: #AAA; border: 1px solid; border-radius: 3px; line-height: 0; padding: 4px}
.MathJax_Hover_Arrow:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_Hover_Arrow:hover span {background-color: #CCC!important}
</style><style type="text/css">#MathJax_Zoom {position: absolute; background-color: #F0F0F0; overflow: auto; display: block; z-index: 301; padding: .5em; border: 1px solid black; margin: 0; font-weight: normal; font-style: normal; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; -webkit-box-sizing: content-box; -moz-box-sizing: content-box; box-sizing: content-box; box-shadow: 5px 5px 15px #AAAAAA; -webkit-box-shadow: 5px 5px 15px #AAAAAA; -moz-box-shadow: 5px 5px 15px #AAAAAA; -khtml-box-shadow: 5px 5px 15px #AAAAAA; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_ZoomOverlay {position: absolute; left: 0; top: 0; z-index: 300; display: inline-block; width: 100%; height: 100%; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
#MathJax_ZoomFrame {position: relative; display: inline-block; height: 0; width: 0}
#MathJax_ZoomEventTrap {position: absolute; left: 0; top: 0; z-index: 302; display: inline-block; border: 0; padding: 0; margin: 0; background-color: white; opacity: 0; filter: alpha(opacity=0)}
</style><style type="text/css">#MathJax_About {position: fixed; left: 50%; width: auto; text-align: center; border: 3px outset; padding: 1em 2em; background-color: #DDDDDD; color: black; cursor: default; font-family: message-box; font-size: 120%; font-style: normal; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 15px; -webkit-border-radius: 15px; -moz-border-radius: 15px; -khtml-border-radius: 15px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
#MathJax_About.MathJax_MousePost {outline: none}
.MathJax_Menu {position: absolute; background-color: white; color: black; width: auto; padding: 5px 0px; border: 1px solid #CCCCCC; margin: 0; cursor: default; font: menu; text-align: left; text-indent: 0; text-transform: none; line-height: normal; letter-spacing: normal; word-spacing: normal; word-wrap: normal; white-space: nowrap; float: none; z-index: 201; border-radius: 5px; -webkit-border-radius: 5px; -moz-border-radius: 5px; -khtml-border-radius: 5px; box-shadow: 0px 10px 20px #808080; -webkit-box-shadow: 0px 10px 20px #808080; -moz-box-shadow: 0px 10px 20px #808080; -khtml-box-shadow: 0px 10px 20px #808080; filter: progid:DXImageTransform.Microsoft.dropshadow(OffX=2, OffY=2, Color='gray', Positive='true')}
.MathJax_MenuItem {padding: 1px 2em; background: transparent}
.MathJax_MenuArrow {position: absolute; right: .5em; padding-top: .25em; color: #666666; font-size: .75em}
.MathJax_MenuActive .MathJax_MenuArrow {color: white}
.MathJax_MenuArrow.RTL {left: .5em; right: auto}
.MathJax_MenuCheck {position: absolute; left: .7em}
.MathJax_MenuCheck.RTL {right: .7em; left: auto}
.MathJax_MenuRadioCheck {position: absolute; left: .7em}
.MathJax_MenuRadioCheck.RTL {right: .7em; left: auto}
.MathJax_MenuLabel {padding: 1px 2em 3px 1.33em; font-style: italic}
.MathJax_MenuRule {border-top: 1px solid #DDDDDD; margin: 4px 3px}
.MathJax_MenuDisabled {color: GrayText}
.MathJax_MenuActive {background-color: #606872; color: white}
.MathJax_MenuDisabled:focus, .MathJax_MenuLabel:focus {background-color: #E8E8E8}
.MathJax_ContextMenu:focus {outline: none}
.MathJax_ContextMenu .MathJax_MenuItem:focus {outline: none}
#MathJax_AboutClose {top: .2em; right: .2em}
.MathJax_Menu .MathJax_MenuClose {top: -10px; left: -10px}
.MathJax_MenuClose {position: absolute; cursor: pointer; display: inline-block; border: 2px solid #AAA; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; font-family: 'Courier New',Courier; font-size: 24px; color: #F0F0F0}
.MathJax_MenuClose span {display: block; background-color: #AAA; border: 1.5px solid; border-radius: 18px; -webkit-border-radius: 18px; -moz-border-radius: 18px; -khtml-border-radius: 18px; line-height: 0; padding: 8px 0 6px}
.MathJax_MenuClose:hover {color: white!important; border: 2px solid #CCC!important}
.MathJax_MenuClose:hover span {background-color: #CCC!important}
.MathJax_MenuClose:hover:focus {outline: none}
</style></head>
    <body class="article" id="ui-jig-5"><div id="MathJax_Message" style="display: none;"></div>
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	&lt;p class="nojs"&gt;
	&lt;strong&gt;Warning:&lt;/strong&gt;
	The NCBI web site requires JavaScript to function. 
	&lt;a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank"&gt;more...&lt;/a&gt;
	&lt;/p&gt;
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list ui-ncbibasicmenu orientation_hort" id="navcontent" role="menubar"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt" role="presentation"><a class="ui-ncbimenu-link-first" href="http://www.ncbi.nlm.nih.gov/" role="menuitem" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="./PMC3162661_files/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo"></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#resources" tabindex="-1" role="menuitem">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first" role="presentation"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="http://www.ncbi.nlm.nih.gov/static/header_footer_ajax/submenu/#howto" tabindex="-1" role="menuitem">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="http://www.ncbi.nlm.nih.gov/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="http://www.ncbi.nlm.nih.gov/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="http://www.ncbi.nlm.nih.gov/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3162661%2F" id="sign_in">Sign in to NCBI</a><a href="http://www.ncbi.nlm.nih.gov/account/signout/?back_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3162661%2F" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo">
  <h1 class="img_logo"><a href="http://www.ncbi.nlm.nih.gov/pmc/" class="pmc_logo offscreen">PMC</a></h1>
  <div class="NLMLogo">
    <a href="http://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>
    <br>
    <a href="http://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>
  </div>
</div>
    <div class="search"><form method="get" action="http://www.ncbi.nlm.nih.gov/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="clone">Clone</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="nucest">EST</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="nucgss">GSS</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="pubmedhealth">PubMed Health</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbook">ToolKitBook</option><option value="toolkitbookgh">ToolKitBookgh</option><option value="unigene">UniGene</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><div class="ui-ncbiclearbutton-wrap box-shadow"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" config="dictionary:&#39;pmc-search-autocomplete&#39;,disableUrl:&#39;NcbiSearchBarAutoComplCtrl&#39;" autocomplete="off" data-sbconfig="ds:&#39;no&#39;,pjs:&#39;no&#39;,afs:&#39;yes&#39;" aria-haspopup="true" aria-autocomplete="list" role="textbox"><a class="reset" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" style="visibility: hidden;"><img src="./PMC3162661_files/clear.png" alt="Clear input"></a></div></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/limits/">Limits</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/advanced/">Advanced</a>
                    </li><li>
                        <a href="http://www.ncbi.nlm.nih.gov/pmc/journals/">Journal list</a>
                    </li><li class="help">
                        <a target="_blank" href="http://www.ncbi.nlm.nih.gov/books/NBK3825/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <div class="container">
    <div id="maincontent" class="content eight_col col">
        <div class="navlink-box">
            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="http://www.ncbi.nlm.nih.gov/pmc/journals/" class="navlink">Journal List</a></li><li class="archive-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/journals/279/">Br J Clin Pharmacol</a></li><li class="issue-page"><a class="navlink" href="http://www.ncbi.nlm.nih.gov/pmc/issues/199617/">v.72(2); 2011 Aug</a></li><li class="accid">PMC3162661</li></ul>
        </div>

        <!-- Journal banner -->
        <div class="pmc-page-banner whole_rhythm"><div><img src="./PMC3162661_files/logo-brjclinpharm.gif" alt="Logo of brjclinpharm" usemap="#logo-imagemap"><map id="logo-imagemap" name="logo-imagemap"><area alt="Link to Publisher&#39;s site" title="Link to Publisher&#39;s site" shape="default" coords="0,0,499,74" href="http://www.blackwellpublishing.com/journal.asp?ref=0306-5251" target="pmc_ext" ref="reftype=publisher&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CBanner&amp;TO=Publisher%7COther%7CN/A&amp;rendering-type=normal"></map></div> </div>
        
        <!--component id='MainPortlet' label='search-reference'/-->
        
        <!-- Book content -->
        <div class="">
            
        
            
            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [&#39;h2&#39;], headingExclude: &#39;:hidden&#39;" id="ui-jig-1"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="small"><div class="inline_block eight_col va_top"><div><div><span class="cit">Br J Clin Pharmacol. 2011 Aug; 72(2): 321–329. </span></div><div>  <span class="doi">doi:&nbsp; <a href="http://dx.doi.org/10.1111%2Fj.1365-2125.2011.03972.x" target="pmc_ext" ref="reftype=other&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI&amp;rendering-type=normal">10.1111/j.1365-2125.2011.03972.x</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC3162661</span></div></div></div></div></div><h1 class="content-title">Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Allred%20AJ%5Bauth%5D">Alicia J Allred</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Bowen%20CJ%5Bauth%5D">Carolyn J Bowen</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Park%20JW%5Bauth%5D">Jung Wook Park</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Peng%20B%5Bauth%5D">Bin Peng</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Williams%20DD%5Bauth%5D">Daphne D Williams</a>,<sup>1</sup> <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Wire%20MB%5Bauth%5D">Mary Beth Wire</a>,<sup>1</sup> and  <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Lee%20E%5Bauth%5D">Edmund Lee</a><sup>2</sup></div></div><div class="fm-panel small half_rhythm"><div class="fm-authors-info fm-panel hide half_rhythm" id="id396848_ai" style="display:none"><div class="fm-affl" lang="en"><sup>1</sup>GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC, USA</div><div class="fm-affl" lang="en"><sup>2</sup>National University of Singapore, 10 Medical Drive, Singapore 117597</div><div id="cor1">Director Mary Beth Wire PharmD, Clinical Pharmacology, Modeling &amp; Simulation, GlaxoSmithKline, Five Moore Drive, 17.1372A.2B, Research Triangle Park, NC 27709, USA. Tel.: +1 919 483 5852 Fax: +1 919 483 8614 E-mail: <a href="mailto:dev@null" data-email="moc.ksg@eriw.b.yram" class="oemail">moc.ksg@eriw.b.yram</a></div><div id="__fnid983580">Dr. Park is now with Astellas, Three Parkway North, Deerfield IL, USA; Dr. Peng is now with Novartis, 1 South Ridgedale Ave, East Hanover, NJ, USA; Dr. Williams is now with Bristol-Myers Squibb, Princeton, NJ, USA.</div></div><div class="togglers"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="pmctoggle" rid="id396848_ai">Author information <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="pmctoggle" rid="id396848_an">Article notes <span>►</span></a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="pmctoggle" rid="id396848_cpl">Copyright and License information <span>►</span></a></div><div class="fm-article-notes fm-panel hide half_rhythm" id="id396848_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2010 Feb 28; Accepted 2011 Mar 21; Accepted 2011 Mar 25.</div></div><div class="fm-cpl-info fm-panel hide half_rhythm" id="id396848_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>  © 2011 The British Pharmacological Society</div></div></div><div class="links-box fm-panel whole_rhythm"><div class="small"><div>This article has been <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="__abstractid1232254" lang="en" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-7"><span role="menubar"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" title="Go to other sections in this page" role="menuitem" aria-expanded="false" aria-haspopup="true" id="ui-jig-8">Go to:</a></span></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__abstractid1232254title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3>AIM</h3><p id="__p2" class="p p-first-last">Eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist, inhibits the organic anion transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP) <em>in vitro</em>. OATP1B1 is important for hepatic uptake of rosuvastatin and inhibition of this transporter could reduce cholesterol-lowering efficacy and increase the risk of exposure-dependent toxicities. In contrast, BCRP is an efflux transporter and inhibition of this transporter could increase both hepatic and plasma rosuvastatin concentrations, resulting in increased efficacy and toxicity. To determine if co-administration of eltrombopag with rosuvastatin alters plasma rosuvastatin exposure, an open-label study was conducted in 42 healthy adult subjects.</p></div><div id="__sec2" class="sec"><h3>METHODS</h3><p id="__p3" class="p p-first-last">Subjects received rosuvastatin and eltrombopag orally: day 1, rosuvastatin 10 mg single dose; days 6 to 9, eltrombopag 75 mg once daily; day 10, eltrombopag 75 mg once daily and rosuvastatin 10 mg single dose. Adverse event assessments were performed daily and at the follow-up visit. Plasma samples for pharmacokinetic analysis were collected days 1 to 5 and days 10 to 14.</p></div><div id="__sec3" class="sec"><h3>RESULTS</h3><p id="__p4" class="p p-first-last">Co-administration of eltrombopag with rosuvastatin increased geometric mean (90% confidence interval) plasma rosuvastatin AUC(0,∞) by 55% (42%, 69%) and <em>C</em><sub>max</sub> by 103% (82%, 126%) in the overall study population, with a larger interaction in the non-Asian compared with Asian subjects.</p></div><div id="__sec4" class="sec sec-last"><h3>CONCLUSIONS</h3><p id="__p5" class="p p-first-last">Concomitant administration of eltrombopag with rosuvastatin was associated with increased rosuvastatin exposure. The therapeutic index of HMG Co-A reductase inhibitors may be reduced by the concomitant use of eltrombopag. In subjects taking eltrombopag, a reduced dose of HMG Co-A reductase inhibitors may be needed.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">BCRP, drug interaction, eltrombopag, OATP1B1, rosuvastatin</span></div></div><div id="__bodyid402226" class="tsec sec headless whole_rhythm"><div class="boxed-text-box whole_rhythm hide-overflow"><div class="sec"><h3>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT</h3><ul class="unordered" style="list-style-type:disc"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
--><li><div>OATP1B1 is important for hepatic uptake of rosuvastatin and BCRP is important for rosuvastatin absorption and elimination. Eltrombopag inhibits OATP1B1 and BCRP <em>in vitro</em> at clinically relevant concentrations. Inhibition of these transporters could change cholesterol-lowering efficacy and increase the risk of exposure-dependent toxicities. To determine if co-administration of eltrombopag with rosuvastatin alters plasma rosuvastatin exposure, an open-label study was conducted in 42 healthy adult subjects.</div></li></ul></div></div><div class="boxed-text-box whole_rhythm hide-overflow"><div class="sec"><h3>WHAT THIS STUDY ADDS</h3><ul class="unordered" style="list-style-type:disc"><!--
list-behavior=unordered
prefix-word=
mark-type=disc
--><li><div>Concomitant administration of eltrombopag with rosuvastatin was associated with increased rosuvastatin exposure via inhibition of drug transporters. The therapeutic index of HMG Co-A reductase inhibitors may be reduced by the concomitant use of eltrombopag. In subjects taking eltrombopag, a reduced dose of HMG Co-A reductase inhibitors may be needed.</div></li></ul></div></div></div><div id="__sec7" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-9"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-10">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec7title">Introduction</h2><p id="__p8" class="p p-first">Eltrombopag (GlaxoSmithKline) is an oral, nonpeptide thrombopoietin receptor agonist approved for the treatment of chronic immune thrombocytopenia (ITP). It is also being investigated for the treatment of thrombocytopenia due to other aetiologies including chronic liver disease and hepatitis C virus [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b1" rid="b1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901777" role="button" aria-expanded="false" aria-haspopup="true">1</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b3" rid="b3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901804" role="button" aria-expanded="false" aria-haspopup="true">3</a>]. Eltrombopag binds to the transmembrane domain of the thrombopoietin receptor and increases platelet counts by stimulating proliferation and differentiation of megakaryocytes [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b4" rid="b4" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901785" role="button" aria-expanded="false" aria-haspopup="true">4</a>].</p><p id="__p9">In preclinical studies, eltrombopag inhibited the organic anion transporting polypeptide 1B1 (OATP1B1) and breast cancer resistance protein (BCRP). Eltrombopag was also identified as a BCRP substrate <em>in vitro</em>. OATP1B1 is highly expressed in the liver and involved in the hepatic uptake of all HMG-CoA reductase inhibitors (statins) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b5" rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901788" role="button" aria-expanded="false" aria-haspopup="true">5</a>]. OATP1B1 is important for rosuvastatin disposition as demonstrated by genetic polymorphism, where subjects with the homozygous OATP1B1 (<em>SLCO1B1</em>) c.521CC genotype had 65% higher rosuvastatin mean area under the curve (AUC(0,48 h)) than those with the homozygous c.521TT (control) genotype [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901783" role="button" aria-expanded="false" aria-haspopup="true">6</a>]. The OATP1B1 (<em>SLCO1B1</em>) c.388GG genotype in combination with the c.521CC genotype (<em>SLCO1B1</em>*<em>15/</em>*<em>15</em>) has also been associated with higher plasma rosuvastatin exposure [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901790" role="button" aria-expanded="false" aria-haspopup="true">7</a>]. BCRP is an efflux transporter that transports drugs from the liver into bile and also limits intestinal drug absorption. BCRP is important for rosuvastatin disposition as demonstrated by genetic polymorphism, where subjects with the heterozygous BCRP (<em>ABCG2</em>) c.421CA or homozygous c.421AA genotypes had approximately two-fold the rosuvastatin AUC(0,∞) compared with those with the homozygous c.421CC (control) genotype [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901800" role="button" aria-expanded="false" aria-haspopup="true">8</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901803" role="button" aria-expanded="false" aria-haspopup="true">9</a>]. The <em>ABCG2</em> c.421AA genotype was associated with greater reductions in low-density lipoprotein (LDL) cholesterol in subjects receiving rosuvastatin therapy [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b10" rid="b10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901792" role="button" aria-expanded="false" aria-haspopup="true">10</a>].</p><p id="__p10" class="p p-last">Rosuvastatin has known transporter-mediated drug interactions, such as its interaction with gemfibrozil and cyclosporin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b11" rid="b11" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901778" role="button" aria-expanded="false" aria-haspopup="true">11</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b12" rid="b12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901805" role="button" aria-expanded="false" aria-haspopup="true">12</a>]. The objective of this study was to evaluate the impact of eltrombopag on plasma rosuvastatin exposure.</p></div><div id="__sec8" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-11"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-12">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec8title">Methods</h2><div id="__sec9" class="sec sec-first"><h3>Study design</h3><p id="__p11" class="p p-first">An open-label, single sequence study was conducted at clinical research sites in Singapore and the United States in 42 healthy adult men and women. All subjects provided written, informed consent. Subjects received rosuvastatin and eltrombopag orally in the following sequence: day 1, rosuvastatin 10 mg single dose; day 6 through day 9, eltrombopag 75 mg once daily; day 10, eltrombopag 75 mg once daily and rosuvastatin 10 mg single dose. This study was designed and monitored in accordance with Good Clinical Practice and the Declaration of Helsinki. The individual Institutional Review Boards at each study site approved the protocol before the study started.</p><p id="__p12">To ensure treatment compliance and continuous safety monitoring, subjects received all doses of study drugs at the clinical research centre and remained in the clinical research unit from day −1 through day 5 and from days 10 through 14. Subjects returned for a follow-up visit approximately 7 to 14 days after the last dose of study medication. The duration of each individual's participation in the study from initial screening to follow-up was approximately 4 weeks.</p><p id="__p13">Inclusion criteria required that participants be healthy. Male and non-pregnant female subjects 18 to 64 years weighing at least 50 kg for men and 45 kg for women were eligible for enrolment. Candidates were ineligible if they had any clinically relevant abnormality identified by prestudy screening history, physical examination, or laboratory testing, including electrocardiogram (ECG) abnormalities, cardiovascular or coagulation disorders, evidence of drug or alcohol abuse or tobacco use, a positive test for HIV, hepatitis B or hepatitis C virus, or use of prescription or non-prescription medications within 7 days (14 days for enzyme-inducing drugs) before receiving the first dose of study drug.</p><p id="__p14" class="p p-last">Adverse event (AE) assessments were performed daily for the duration of the study and at the follow-up visit. Standard meals were provided on study day −1 to day 5 and days 10 to 14. Participants fasted 8 h before and 4 h after administration of either study drug. Serial 3 ml blood samples for pharmacokinetic (PK) analysis were collected prior to and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, 48, 60, 72, 84 and 96 h after single dose rosuvastatin administration on days 1 and 10. A blood sample was obtained on day −1 for the purpose of genotyping the OATP1B1 (<em>SLCO1B1</em>), BCRP (<em>ABCG</em>2) and NTCP [sodium taurocholate co-transporting polypeptide (<em>SLC10A1</em>)] transporters.</p></div><div id="__sec10" class="sec sec-last"><h3>Analyses</h3><p id="__p15" class="p p-first">Genotyping for polymorphisms in OATP1B1 (<em>SLCO1B1</em>) T521C and A388G and BCRP (<em>ABCG2</em>) C421A and NTCP (<em>SLC10A1</em>) exon 3 *3 and exon 4 *2, *4, and *5 was done. Regions spanning the single nucleotide polymorphisms (SNPs) of interest were first amplified from genomic DNA via polymerase chain reaction (PCR) using specific primers as presented in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl1/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl1" rid-ob="ob-tbl1" co-legend-rid=""><span>Table 1</span></a>. PCR product sizes and purity were confirmed by agarose gel electrophoresis against a 100 base pair (bp) molecular weight marker.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl1"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl1/" target="table" rid-ob="ob-tbl1" rid-figpopup="tbl1" class="table img_link icnblk_img figpopup"><img alt="Table 1" title="Table 1" class="small-thumb" src="./PMC3162661_files/saved_resource" src-large="/pmc/articles/PMC3162661/table/tbl1/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl1/" target="table" rid-figpopup="tbl1" rid-ob="ob-tbl1">Table 1</a></div><!--caption a4--><div><span>Primer sequences</span></div></div></div><p id="__p18">For OATP1B1 (<em>SLCO1B1</em>) T521C and A388G, and NTCP (<em>SLC10A1</em>) exon 3 *3 and exon 4 *2, *4, and *5, the amplified fragments were subsequently analyzed by bidirectional sequencing using Bigdye V3.1 termination cycle sequencing kit (Applied Biosystems, Foster City, CA) on an ABI Avant 3100 genetic analyzer (Applied Biosystems). All polymorphisms were called using mutation analysis software (Mutation Surveyor V5.1) and qualified additionally by predetermined sample controls.</p><p id="__p19">The BCRP (<em>ABCG2</em>) C421A polymorphism was genotyped by Taa I PCR restriction fragment length polymorphism. Briefly, the amplified 289 bp PCR fragment encompassing the SNP of interest was subsequently incubated at 65°C with three units of a restriction enzyme (Taa I) for 3 h. The digested amplified products were loaded onto a 3% agarose gel to verify digested product sizes. A wt/wt (cc/cc) genotype would reveal a digested product size of 256 bp whereas a mt/mt (aa/aa) genotype would resist digestion by the enzyme to remain at 289 bp. Heterozygous genotypes exhibit both product sizes (289 bp and 256 bp).</p><p id="__p20">Plasma PK samples collected on days 1 and 10 were assayed for rosuvastatin using a validated analytical method based on solid phase extraction, followed by high-performance liquid chromatography coupled to tandem mass spectrometry (HPLC/MS/MS) analysis. Using a 100 µl aliquot of plasma, the lower limit of quantification for the rosuvastatin assay was 0.2 ng ml<sup>−1</sup> and the higher limit of quantification was 30 ng ml<sup>−1</sup>. Each batch of plasma samples was run against freshly prepared duplicate calibration standards (<em>n</em> = 8). Imprecision and inaccuracy between assays were &lt;14%. Quality control (QC) samples at three concentrations (0.5, 5, and 25 ng ml<sup>−1</sup>) were assayed along with study samples and the calculated QC sample concentrations deviated by &lt;15% from the actual concentrations. Plasma PK samples collected on day 10 were assayed for eltrombopag using a validated analytical method based on protein precipitation, followed by HPLC/MS/MS analysis. Using a 50 µl aliquot of plasma, the lower limit of quantification for the eltrombopag assay was 100 ng ml<sup>−1</sup> and the higher limit of quantification was 50 000 ng ml<sup>−1</sup>. Each batch of plasma samples was run against freshly prepared duplicate calibration standards (<em>n</em> = 9). Imprecision and inaccuracy between assays were &lt;14%. QC samples at three concentrations (400, 4000, and 40 000 ng ml<sup>−1</sup>) were assayed along with study samples and the calculated QC sample concentrations deviated by &lt;15% from the actual concentrations.</p><p id="__p21">The primary PK endpoints were maximum plasma concentration (<em>C</em><sub>max</sub>) and area under the plasma concentration <em>vs</em>. time curve starting from dosing and extrapolated to infinity (AUC(0,∞)) of rosuvastatin when administered alone or co-administered with eltrombopag. <em>C</em><sub>max</sub> and the first time to reach <em>C</em><sub>max</sub> (<em>t</em><sub>max</sub>) were the actual observed values. The AUC was calculated using the linear trapezoidal rule for each incremental trapezoid and the log trapezoidal rule for each decremental trapezoid. The AUC from time zero to the last measurable concentration (AUC(0,τ)) and AUC(0,∞) was determined. Values for AUC(0,∞) were estimated as the sum of AUC(0,τ) and <em>C<sub>t</sub></em> divided by the elimination rate constant (λ<sub>z</sub>), where <em>C<sub>t</sub></em> was the last observed quantifiable concentration.</p><p id="__p22">Steady-state plasma eltrombopag <em>C</em><sub>max</sub> and AUC over a dosing interval (AUC(0,τ)) were estimated for the combination regimen only. In addition, plasma eltrombopag trough concentrations collected on day 10 prior to administration of rosuvastatin and 24 h after rosuvastatin co-administration were measured.</p><p id="__p23">To assess the effects of eltrombopag on rosuvastatin PK, log transformed plasma rosuvastatin AUC(0,∞) and <em>C</em><sub>max</sub> were analyzed separately by analysis of variance (<span class="small-caps">anova</span>) fitting terms for treatment and subject. Point estimates and associated 90% confidence intervals (CI) for the differences were constructed using the appropriate error term. The point and interval estimates on the log scale were then back-transformed to give point and interval estimates for the ratios. Plasma eltrombopag and rosuvastatin PK parameters were summarized by treatment and by race and gender within treatment. Plasma rosuvastatin concentration–time profiles were plotted by treatment, race and gender. Plasma rosuvastatin AUC(0,∞) was plotted by genotype combination (approach 2 as described in the following paragraph). Subgroup analyses were conducted as secondary analyses. Similar to the primary statistical analysis, plasma rosuvastatin PK values were compared between treatments for subgroups based on race (Asian <em>vs.</em> non-Asian) and gender.</p><p id="__p24" class="p p-last">Multivariate analyses of the relationship between day 1 plasma rosuvastatin AUC(0,∞) and <em>C</em><sub>max</sub> and potential covariates was completed. The analysis included race (Asian <em>vs.</em> non-Asian), gender, body weight, and OATP1B1 (<em>SLCO1B1</em>) A388G and T521C and BCRP (<em>ABCG2</em>) C421A genotypes. Genotypes were included three ways. Approach 1: each gene variant was included separately. Approach 2: <em>SLCO1B1</em> haplotype and <em>ABCG2</em> genotype combinations were categorized, Category 1 included <em>SLCO1B1</em> haplotypes *1a/*1a, *1a/*1b, and *1b/*1b, Category 2 included <em>SLCO1B1</em> haplotypes *1a/*15 and *1b/*15, Category 3 included the <em>ABCG2</em> c.421CA genotype in combination with <em>SLCO1B1</em> haplotypes *1a/*1a, *1a/*1b, or *1b/*1b and Category 4 included the <em>ABCG2</em> c.421CA genotype in combination with <em>SLCO1B1</em> haplotypes *1b/*15 or *15/*15 and the <em>ABCG2</em> c.421AA genotype in combination with <em>SLCO1B1</em> haplotype *1b/*1b. Approach 3: combinations of gene variants c.388AA, c.388AG, c.521TT, c.521TC and c.421CC were assigned zero, c.388GG, c.521CC and c.421CA were assigned 1 and c.421AA was assigned 2, and the scores were summed across the three gene variants (possible score of 0 to 4).</p></div></div><div id="__sec11" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-13"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-14">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec11title">Results</h2><div id="__sec12" class="sec sec-first"><h3>Demographics and genotypes</h3><p id="__p25" class="p p-first">Similar numbers of Asian and non-Asian subjects were enrolled in the study (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl2/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl2" rid-ob="ob-tbl2" co-legend-rid=""><span>Table 2</span></a>). Of the genotypes evaluated in the current study, only the OATP1B1 (<em>SLCO1B1</em>) A388G genotypes were relatively evenly distributed overall and within Asian and non-Asian groups (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl3/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). The majority of subjects had homozygous wild-type OATP1B1 (<em>SLCO1B1</em>) c.521TT and BCRP (<em>ABCG2</em>) c.421CC genotypes, with 20 to 40% having the heterozygous genotype (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl3/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>). There was a broad range of OATP1B1 (<em>SLCO1B1</em>) haplotype and BCRP (<em>ABCG2</em>) genotype combinations (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl3/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl3" rid-ob="ob-tbl3" co-legend-rid=""><span>Table 3</span></a>).</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl2"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl2/" target="table" rid-ob="ob-tbl2" rid-figpopup="tbl2" class="table img_link icnblk_img figpopup"><img alt="Table 2" title="Table 2" class="small-thumb" src="./PMC3162661_files/saved_resource(1)" src-large="/pmc/articles/PMC3162661/table/tbl2/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl2/" target="table" rid-figpopup="tbl2" rid-ob="ob-tbl2">Table 2</a></div><!--caption a4--><div><span>Subject disposition and demographics</span></div></div></div><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl3"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl3/" target="table" rid-ob="ob-tbl3" rid-figpopup="tbl3" class="table img_link icnblk_img figpopup"><img alt="Table 3" title="Table 3" class="small-thumb" src="./PMC3162661_files/saved_resource(2)" src-large="/pmc/articles/PMC3162661/table/tbl3/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl3/" target="table" rid-figpopup="tbl3" rid-ob="ob-tbl3">Table 3</a></div><!--caption a4--><div><span>Summary of genotype frequency</span></div></div></div></div><div id="__sec13" class="sec"><h3>Pharmacokinetics</h3><p id="__p31" class="p p-first">Race (<em>P</em> &lt; 0.001) and gender (<em>P</em> &lt; 0.05) were retained as significant predictors of plasma rosuvastatin AUC(0,∞) and <em>C</em><sub>max</sub> in the final multivariate models where genotype by approach 1 and approach 2 were tested. Race (<em>P</em> &lt; 0.001), gender (<em>P</em> &lt; 0.05) and genotype (<em>P</em> &lt; 0.05) were retained in the final model as significant predictors of plasma rosuvastatin AUC(0,∞) and <em>C</em><sub>max</sub> where genotype by approach 3 was tested. Body weight was not a significant covariate in any of the analyses. Only one of 21 Asian subjects was female, so the gender effect was driven by data within the non-Asian group (seven of 18 non-Asian subjects were female). Asian participants had a 109% higher rosuvastatin AUC(0,∞) and a 139% higher <em>C</em><sub>max</sub> compared with non-Asian subjects when rosuvastatin was administered alone (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl4/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob="ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). Within the non-Asian population, female participants had 50% higher rosuvastatin AUC(0,∞) and 84% higher <em>C</em><sub>max</sub> compared with male subjects when rosuvastatin was administered alone.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl4"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl4/" target="table" rid-ob="ob-tbl4" rid-figpopup="tbl4" class="table img_link icnblk_img figpopup"><img alt="Table 4" title="Table 4" class="small-thumb" src="./PMC3162661_files/saved_resource(3)" src-large="/pmc/articles/PMC3162661/table/tbl4/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl4/" target="table" rid-figpopup="tbl4" rid-ob="ob-tbl4">Table 4</a></div><!--caption a4--><div><span>Summary of plasma rosuvastatin pharmacokinetics and treatment comparisons</span></div></div></div><p id="__p37">Co-administration of eltrombopag with rosuvastatin increased plasma rosuvastatin AUC(0,∞) by 55% and <em>C</em><sub>max</sub> by 103% in the overall study population compared with administration of rosuvastatin alone (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl4/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob="ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). The impact of eltrombopag on plasma rosuvastatin exposure differed by race. Plasma rosuvastatin AUC(0,∞) increased by 88% and <em>C</em><sub>max</sub> increased 165% in non-Asian subjects, whereas AUC(0,∞) increased by 32% and <em>C</em><sub>max</sub> increased 61% in Asian subjects (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl4/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob="ob-tbl4" co-legend-rid=""><span>Table 4</span></a>). Median plasma rosuvastatin concentration–time profiles are displayed for the overall population and by race for each treatment in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/figure/fig01/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig01" rid-ob="ob-fig01" co-legend-rid="lgnd_fig01"><span>Figure 1</span></a>. The impact of eltrombopag on plasma rosuvastatin exposure appeared to differ by gender within the non-Asian population (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl4/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob="ob-tbl4" co-legend-rid=""><span>Table 4</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig01" co-legend-rid="lgnd_fig01"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01"><img src="./PMC3162661_files/bcp0072-0321-f1.gif" class="small-thumb" alt="Figure 1" title="Figure 1" src-large="/pmc/articles/PMC3162661/bin/bcp0072-0321-f1.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig01"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/figure/fig01/" target="figure" rid-figpopup="fig01" rid-ob="ob-fig01">Figure 1</a></div><!--caption a4--><div><span>Median plasma rosuvastatin concentration–time profiles. rosuvastain alone (no symbol = rosuvastain + eltrombopag) (▴); overall population (<img alt="An external file that holds a picture, illustration, etc.
Object name is bcp0072-0321-mu1.jpg" src="./PMC3162661_files/bcp0072-0321-mu1.jpg" class="equation">); Asian (<img alt="An external file that holds a picture, illustration, etc.
Object name is bcp0072-0321-mu2.jpg" src="./PMC3162661_files/bcp0072-0321-mu2.jpg" class="equation">); non-Asian (<img alt="An external file that holds a picture, illustration, etc.
Object name is bcp0072-0321-mu3.jpg" src="./PMC3162661_files/bcp0072-0321-mu3.jpg" class="equation">)</span></div></div></div><p id="__p39">Subjects with combined genotype scores (approach 3) of 2–3 had higher plasma rosuvastatin exposures than subjects with scores of 0–1, and there was also a trend for higher plasma rosuvastatin exposures for subjects in category 4 (approach 2). However, given the small sample size, it is difficult to draw firm conclusions regarding the relationship between genotype and plasma rosuvastatin exposure. Plasma rosuvastatin AUC(0,∞) <em>vs</em>. genotype combination (approach 2) are displayed in <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>, along with race and gender details.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock ten_col whole_rhythm clearfix" id="fig02" co-legend-rid="lgnd_fig02"><a class="icnblk_img figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02"><img src="./PMC3162661_files/bcp0072-0321-f2.gif" class="small-thumb" alt="Figure 2" title="Figure 2" src-large="/pmc/articles/PMC3162661/bin/bcp0072-0321-f2.jpg"></a><div class="icnblk_cntnt" id="lgnd_fig02"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/figure/fig02/" target="figure" rid-figpopup="fig02" rid-ob="ob-fig02">Figure 2</a></div><!--caption a4--><div><span>Plasma rosuvastatin AUC(0,∞) by OATP1B1 (<em>SLCO1B1</em>) haplotype and BCRP (<em>ABCG2</em>) C421A genotype. non-Asian male (□); Asian male (○); non-Asian female (<img alt="An external file that holds a picture, illustration, etc.
Object name is bcp0072-0321-mu4.jpg" src="./PMC3162661_files/bcp0072-0321-mu4.jpg" class="equation">); Asian female (•)</span></div></div></div><p id="__p41" class="p">For the overall population, the geometric mean of plasma eltrombopag <em>C</em><sub>max</sub> was 8.00 µg ml<sup>−1</sup> and AUC(0,τ) was 102 µg ml<sup>−1</sup> h, and plasma eltrombopag exposures were similar between Asian and non-Asian subjects and between the BCRP (<em>ABCG2</em>) c.421CC and c.421CA genotypes (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl5/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl5" rid-ob="ob-tbl5" co-legend-rid=""><span>Table 5</span></a>). The one subject (Asian male) with the c.421AA genotype had the highest plasma eltrombopag AUC(0,τ) (247 µg ml<sup>−1</sup> h), but the exposure was similar to the highest AUC(0,τ) (227 µg ml<sup>−1</sup> h) observed for an Asian male subject with the c.421CC genotype. When races were combined, plasma eltrombopag exposure was similar between males and females (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl5/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl5" rid-ob="ob-tbl5" co-legend-rid=""><span>Table 5</span></a>), but within the non-Asian group, women had approximately 46% higher plasma eltrombopag AUC(0,τ) (126 <em>vs.</em> 86 µg ml<sup>−1</sup> h) and 37% higher <em>C</em><sub>max</sub> (9.48 <em>vs.</em> 6.94 µg ml<sup>−1</sup>). Median (range) eltrombopag trough concentrations of 2.98 µg ml<sup>−1</sup> (1.14–6.97 µg ml<sup>−1</sup>) collected on day 10 prior to co-administration of rosuvastatin were similar to trough concentrations of 3.22 µg ml<sup>−1</sup> (1.22–6.94 µg ml<sup>−1</sup>) collected 24 h after co-administration of a single dose of rosuvastatin.</p><!--table ft1--><!--table-wrap mode=article t1--><div class="table-wrap iconblock ten_col whole_rhythm clearfix" id="tbl5"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl5/" target="table" rid-ob="ob-tbl5" rid-figpopup="tbl5" class="table img_link icnblk_img figpopup"><img alt="Table 5" title="Table 5" class="small-thumb" src="./PMC3162661_files/saved_resource(4)" src-large="/pmc/articles/PMC3162661/table/tbl5/?report=previmg"></a><div class="icnblk_cntnt"><div><a class="figpopup" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl5/" target="table" rid-figpopup="tbl5" rid-ob="ob-tbl5">Table 5</a></div><!--caption a4--><div><span>Summary of plasma eltrombopag pharmacokinetics</span></div></div></div></div><div id="__sec14" class="sec sec-last"><h3>Safety</h3><p id="__p45" class="p p-first-last">AEs were reported by 10% to 21% of subjects per treatment. AEs reported by more than one subject on a given treatment included gastroenteritis, headache and upper respiratory infection. No serious AEs were reported by study participants. Subjects experienced no clinically significant changes in vital signs, ECG abnormalities or QT<sub>c</sub> prolongation. Increased platelet counts were observed in several subjects following administration of eltrombopag. At the follow-up visit, 16 subjects (38%) had platelet counts &gt;400 Gi l<sup>−1</sup> (range 415–684 Gi l<sup>−1</sup>), the upper limit of normal. Changes from baseline in these individuals ranged from 32% to 113%. In these subjects, platelet counts decreased to normal no later than day 117. Because lens changes have been observed in preclinical animal studies and in clinical studies, ophthalmic assessments were conducted in this study. No changes in ocular status due to cataracts were observed during the study.</p></div></div><div id="__sec15" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-15"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-16">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec15title">Discussion</h2><p id="__p46" class="p p-first">This study was conducted because <em>in vitro</em> data identified eltrombopag as an inhibitor of both OATP1B1 and BCRP with I<em>C</em><sub>50</sub>s of 2.7 µ<span class="small-caps">m</span> (1.19 µg ml<sup>−1</sup>). Eltrombopag concentrations achieved clinically are higher than this I<em>C</em><sub>50</sub> value (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl5/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl5" rid-ob="ob-tbl5" co-legend-rid=""><span>Table 5</span></a>), and OATP1B1 and BCRP are important for rosuvastatin disposition. Statins are widely used cholesterol-lowering agents [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901786" role="button" aria-expanded="false" aria-haspopup="true">13</a>] and are generally used as chronic therapy, but they are associated with significant toxicities, such as rhabdomyolysis and increases in liver transaminases, the incidence of which can increase in the presence of elevated plasma drug concentrations. In addition, the efficacy of statins can be reduced if their uptake into the liver is impaired. Thus, drug interactions involving statins can be clinically important for both safety and efficacy. The central finding of the study was that co-administration of eltrombopag 75 mg once daily with a single dose of rosuvastatin 10 mg increased plasma rosuvastatin <em>C</em><sub>max</sub> by 103% and AUC(0,∞) by 55% in the overall study population compared with rosuvastatin alone (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl4/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob="ob-tbl4" co-legend-rid=""><span>Table 4</span></a>).</p><p id="__p47">Because it was known that Asian subjects have higher rosuvastatin exposures than non-Asian subjects [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901784" role="button" aria-expanded="false" aria-haspopup="true">7</a>], this study enrolled subjects at one site in Singapore and one site in the United States. Consistent with previous data, Asian race was associated with higher plasma rosuvastatin exposure, with Asian subjects having approximately twice the exposure as non-Asian subjects enrolled in the current study when rosuvastatin was given alone. Interestingly, the non-Asian group studied by Lee <em>et al</em>. [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901793" role="button" aria-expanded="false" aria-haspopup="true">7</a>] was composed of White subjects, whereas the non-Asian group in the current study included a high percentage of African American subjects. The observed interindividual variability in plasma rosuvastatin exposure could be due to different genetic polymorphisms that encode drug-metabolizing transporters [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b14" rid="b14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901796" role="button" aria-expanded="false" aria-haspopup="true">14</a>]. It was anticipated that inhibition of OATP1B1 by eltrombopag would have a lesser effect on plasma rosuvastatin exposure in Asian subjects compared with non-Asian subjects, whose transporter activity is more functional, and this was confirmed when the drug interaction results were summarized by race (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/table/tbl4/" target="true" class="fig-table-link table figpopup" rid-figpopup="tbl4" rid-ob="ob-tbl4" co-legend-rid=""><span>Table 4</span></a>).</p><p id="__p48">OATP1B1 (<em>SLCO1B1</em>) T521C polymorphisms independently and in combination with the c.388GG polymorphisms (<em>SLCO1B1</em>*<em>15/</em>*<em>15</em>) have not been associated with racial differences in rosuvastatin PK, but have been associated with rosuvastatin PK variability in White subjects [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b7" rid="b7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901782" role="button" aria-expanded="false" aria-haspopup="true">7</a>]. BCRP C421A polymorphisms have been associated with rosuvastatin PK variability as well [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901799" role="button" aria-expanded="false" aria-haspopup="true">8</a>]. The study was not designed to stratify enrolment by <em>SLCO1B1</em> A388G, <em>SLCO1B</em>1 T521A or <em>ABCG2</em> C421T genotypes or by <em>SLCO1B1</em> haplotype and <em>ABCG2</em> C421A genotype combinations. Of the gene variants evaluated in the current study, only <em>SLCO1B1</em> A388G genotypes, which have not been independently associated with plasma rosuvastatin exposure, were relatively evenly distributed across the enrolled population. In a multivariate analysis where each gene variant was included separately, genotype was not significantly associated with plasma rosuvastatin exposure when race, gender and body weight were included in the model. In multivariate analyses including <em>SLCO1B1</em> haplotype and <em>ABCG2</em> genotype combinations, there was some association between haplotype and genotype combinations and plasma rosuvastatin exposure when race, gender and body weight were included in the model, but given the small sample size within each combination, it is difficult to draw conclusions (<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/figure/fig02/" target="figure" class="fig-table-link fig figpopup" rid-figpopup="fig02" rid-ob="ob-fig02" co-legend-rid="lgnd_fig02"><span>Figure 2</span></a>).</p><p id="__p49">The finding of statistically significant higher plasma rosuvastatin exposures in female subjects has not been reported in the literature to our knowledge. However, there was a trend for higher exposures reported for Chinese female healthy volunteers [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b15" rid="b15" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901791" role="button" aria-expanded="false" aria-haspopup="true">15</a>].</p><p id="__p50">Because the <em>in vitro</em> inhibition potency of eltrombopag is similar for OATP1B1 and BCRP and because genetic polymorphisms in both transporters are known to be associated with rosuvastatin exposure, it is probable that the increased rosuvastatin exposure observed with eltrombopag co-administration is due to inhibition of both transporters. Inhibition of OATP1B1 increases plasma rosuvastatin exposure by reducing the hepatic uptake; in this scenario, rosuvastatin efficacy may be reduced and toxicity may be increased. In contrast, inhibition of BCRP increases plasma rosuvastatin exposure by enhancing rosuvastatin absorption and/or by inhibiting rosuvastatin elimination in the bile; in this scenario rosuvastatin efficacy and toxicity may both be increased. <em>In vitro</em> evidence also suggests that rosuvastatin is a substrate for other hepatic uptake transporters including OATP1B3, OATP2B1, OATP1A2, as well as a substrate for the bile acid uptake transporter NTCP [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901795" role="button" aria-expanded="false" aria-haspopup="true">13</a>]. It is not known if eltrombopag has an impact on these other transporters.</p><p id="__p51">OATP1B1 is highly expressed on the basolateral (sinusoidal) membrane of hepatocytes and involved in the hepatic uptake of all HMG-CoA reductase inhibitors (statins) [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b5" rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901801" role="button" aria-expanded="false" aria-haspopup="true">5</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b13" rid="b13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901779" role="button" aria-expanded="false" aria-haspopup="true">13</a>]. However, the importance of OATP1B1 on the HMG-CoA reductase inhibitors' disposition varies among the drugs of this class. For example, subjects with the homozygous OATP1B1 (<em>SLCO1B1</em>) 521CC genotype had 1.65- to 3.21-fold higher exposures of rosuvastatin, pravastatin, simvastatin, lovastatin and atorvastatin than those with the homozygous 521TT (control) genotypes [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b6" rid="b6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901781" role="button" aria-expanded="false" aria-haspopup="true">6</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b16" rid="b16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901802" role="button" aria-expanded="false" aria-haspopup="true">16</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b17" rid="b17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901776" role="button" aria-expanded="false" aria-haspopup="true">17</a>]. In contrast, fluvastatin exposure was not different among the T521C genotypes, further suggesting that OATP1B1 may not be important for fluvastatin disposition. BCRP is highly expressed on the apical membrane of enterocytes of the small intestine and the bile canalicular membrane of the hepatocyte and involved in the efflux of some statins out of the intestine and into the bile. BCRP polymorphisms have been associated with rosuvastatin, atorvastatin, fluvastatin and simvastatin lactone (but not acid), but not pravastatin or pitavastatin [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b8" rid="b8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901798" role="button" aria-expanded="false" aria-haspopup="true">8</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b9" rid="b9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901780" role="button" aria-expanded="false" aria-haspopup="true">9</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b18" rid="b18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901789" role="button" aria-expanded="false" aria-haspopup="true">18</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b19" rid="b19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901797" role="button" aria-expanded="false" aria-haspopup="true">19</a>].</p><p id="__p52">Given that exposures to several HMG-CoA reductase inhibitors are associated with OATP1B1 (<em>SLCO1B1</em>) and/or BCRP (<em>ABCG2</em>) polymorphisms, the results of the eltrombopag-rosuvastatin interaction study may be extended to other statins. In subjects who were co-administered eltrombopag and rosuvastatin, increased rosuvastatin <em>C</em><sub>max</sub> (mean 103% increase) and AUC(0,∞) (mean 55% increase) were observed. This suggests that clinicians should consider reducing a subject's dose of statin when co-administered with eltrombopag. Monitoring side effects, clinical chemistry, and lipid concentrations is warranted in subjects receiving both eltrombopag and a statin. As noted by other investigators, most clinically significant drug–drug interactions involving lipid-lowering drugs can be avoided by appropriate drug selection and dosing [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b5" rid="b5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901787" role="button" aria-expanded="false" aria-haspopup="true">5</a>].</p><p id="__p53">The impact of rosuvastatin on plasma eltrombopag PK was not formally assessed. However, eltrombopag trough concentrations collected prior to co-administration of rosuvastatin were similar to trough concentrations collected 24 h after co-administration of a single dose of rosuvastatin. In addition, plasma eltrombopag exposure for the 75 mg once daily regimen (in combination with a single dose of rosuvastatin) was generally as expected based on plasma eltrombopag exposures observed in other eltrombopag studies [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b20" rid="b20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_230901794" role="button" aria-expanded="false" aria-haspopup="true">20</a>–<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b22" rid="b22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_310502497" role="button" aria-expanded="false" aria-haspopup="true">22</a>]. Therefore, there does not appear to be a significant impact of rosuvastatin on plasma eltrombopag PK.</p><p id="__p54">Plasma eltrombopag exposures collected in the presence of rosuvastatin were similar between Asian and non-Asian subjects. This is inconsistent with previous studies that have shown approximately two-fold higher plasma eltrombopag exposures in Asian <em>vs.</em> non-Asian subjects [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b21" rid="b21" class=" bibr popnode" role="button" aria-expanded="false" aria-haspopup="true">21</a>, <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b22" rid="b22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_310502495" role="button" aria-expanded="false" aria-haspopup="true">22</a>]. In these prior studies, the non-Asian populations were predominantly White/Caucasian, whereas, in the current study, the non-Asian population included a high percentage of African Americans. Within the non-Asian population, female subjects had higher plasma eltrombopag exposure, which is consistent with previous reports [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b22" rid="b22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_310502496" role="button" aria-expanded="false" aria-haspopup="true">22</a>]. Eltrombopag is a BCRP substrate and plasma eltrombopag exposure was similar between c.421CC and c.421CA genotypes. Although the one subject (Asian male) with the c.421AA genotype had the highest plasma eltrombopag AUC(0,τ) (247 µg ml<sup>−1</sup> h), the exposure was similar to the highest AUC(0,τ) (227 µg ml<sup>−1</sup> h) observed for an Asian male subject with the c.421CC genotype. Given the limited data for the c.421AA genotype, no conclusions can be drawn as to whether this genotype is associated with plasma eltrombopag exposure.</p><p id="__p55" class="p p-last">In conclusion, concomitant administration of eltrombopag with rosuvastatin was associated with increased rosuvastatin exposure. The therapeutic index of HMG Co-A reductase inhibitors may be reduced by the concomitant use of eltrombopag. In subjects taking eltrombopag, a reduced dose of HMG Co-A reductase inhibitors may be needed.</p></div><div id="__ackid1222795" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-17"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-18">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ackid1222795title">Acknowledgments</h2><div class="sec"><p id="__p56">The authors thank Mark Dana, Sandra Saouaf, PhD and AOI Communications, L.P., for assistance in preparing this manuscript.</p></div></div><div id="__sec16" class="tsec bk-sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-19"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-20">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__sec16title">Competing Interests</h2><!--/article/back/sec/--><p id="__p57" class="p p-first-last">Alicia Allred, Carolyn Bowen and Mary Beth Wire are employees of GlaxoSmithKline (GSK), and are stock holders. Bin Peng and Jung Wook Park were employees of GSK during the time that the study was conducted, and are stock holders. Daphne Williams was an employee of GSK during the time that the study was conducted. Edmund Lee does not have conflicts of interest to disclose.</p></div><div id="__ref-listid1222816" class="tsec sec"><div class="goto jig-ncbiinpagenav-goto-container" id="ui-jig-21"><a class="tgt_dark page-toc-label jig-ncbiinpagenav-goto-heading" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" title="Go to other sections in this page" role="button" aria-expanded="false" aria-haspopup="true" id="ui-jig-22">Go to:</a></div><h2 class="head no_bottom_margin ui-helper-clearfix" id="__ref-listid1222816title">REFERENCES</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="b1">1. <span class="element-citation">Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. <span><span class="ref-journal">Lancet. </span>2009;<span class="ref-vol">373</span>:641–8.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19231632" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b2">2. <span class="element-citation">Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. <span><span class="ref-journal">N Engl J Med. </span>2007;<span class="ref-vol">357</span>:2237–47.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18046028" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b3">3. <span class="element-citation">McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH. Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. <span><span class="ref-journal">N Engl J Med. </span>2007;<span class="ref-vol">357</span>:2227–36.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18046027" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b4">4. <span class="element-citation">Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM. Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist. <span><span class="ref-journal">Stem Cells. </span>2009;<span class="ref-vol">27</span>:424–30.</span> <span class="nowrap ref pmc">[<a class="int-reflink" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2729672/">PMC free article</a>]</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19038790" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b5">5. <span class="element-citation">Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2006;<span class="ref-vol">80</span>:565–81.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17178259" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b6">6. <span class="element-citation">Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M. Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2007;<span class="ref-vol">82</span>:726–33.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17473846" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b7">7. <span class="element-citation">Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2005;<span class="ref-vol">78</span>:330–41.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16198652" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b8">8. <span class="element-citation">Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen J, Huang YF, Zhou HH. Role of BCRP 421C&gt;A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. <span><span class="ref-journal">Clin Chim Acta. </span>2006;<span class="ref-vol">373</span>:99–103.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16784736" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b9">9. <span class="element-citation">Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M. ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2009;<span class="ref-vol">86</span>:197–203.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19474787" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b10">10. <span class="element-citation">Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK. ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2010;<span class="ref-vol">87</span>:558–62.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20130569" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b11">11. <span class="element-citation">Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2004;<span class="ref-vol">75</span>:455–63.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15116058" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b12">12. <span class="element-citation">Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2004;<span class="ref-vol">76</span>:167–77.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b13">13. <span class="element-citation">Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. <span><span class="ref-journal">Gastroenterology. </span>2006;<span class="ref-vol">130</span>:1793–806.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16697742" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b14">14. <span class="element-citation">Smith NF, Figg WD, Sparreboom A. Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination. <span><span class="ref-journal">Expert Opin Drug Metab Toxicol. </span>2005;<span class="ref-vol">1</span>:429–45.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16863454" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b15">15. <span class="element-citation">Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study. <span><span class="ref-journal">Clin Ther. </span>2007;<span class="ref-vol">29</span>:2194–203.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18042475" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b16">16. <span class="element-citation">Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2006;<span class="ref-vol">80</span>:356–66.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17015053" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b17">17. <span class="element-citation">Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. <span><span class="ref-journal">Pharmacogenet Genomics. </span>2006;<span class="ref-vol">16</span>:873–9.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17108811" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b18">18. <span class="element-citation">Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M. Different effects of the ABCG2 c.421C&gt;A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin. <span><span class="ref-journal">Pharmacogenomics. </span>2009;<span class="ref-vol">10</span>:1617–24.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19842935" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b19">19. <span class="element-citation">Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y. SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. <span><span class="ref-journal">Clin Pharmacol Ther. </span>2007;<span class="ref-vol">82</span>:541–7.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17460607" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b20">20. <span class="element-citation">Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL. Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist. <span><span class="ref-journal">Blood. </span>2007;<span class="ref-vol">109</span>:4739–41.</span>  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17327409" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="b21">21. <span class="element-citation">PROMACTA® (eltrombopag) <span class="ref-journal">Full Prescribing Information.</span> Research Triangle Park, NC: GlaxoSmithKline; 2008. </span></div><div class="ref-cit-blk half_rhythm" id="b22">22. <span class="element-citation">Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura. <span><span class="ref-journal">J Clin Pharmacol. </span>2010</span> [Epub ahead of print]  <span class="nowrap ref pubmed">[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20663993" target="pmc_ext" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord&amp;rendering-type=normal">PubMed</a>]</span></span></div></div></div><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu"><ul id="ui-ncbiinpagenav-2"><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#__abstractid1232254title">Abstract</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#__sec7title">Introduction</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#__sec8title">Methods</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#__sec11title">Results</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#__sec15title">Discussion</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#__ackid1222795title">Acknowledgments</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#__sec16title">Competing Interests</a></li><li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#__ref-listid1222816title">REFERENCES</a></li></ul></div></div><!--post-content--><hr class="whole_rhythm no_bottom_margin"><div class="courtesy-note no_margin small">Articles from <span class="acknowledgment-journal-title">British Journal of Clinical Pharmacology</span> are provided here courtesy of <strong>British Pharmacological Society</strong></div></div>
            
            
        
            
        </div>
        <!-- Book content -->
    </div>
    
    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            
        </div>
        
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="try-button"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/?report=reader"><img src="./PMC3162661_files/3838809" alt="PubReader format: click here to try"></a></div><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/epub/">ePub (beta)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/pdf/bcp0072-0321.pdf">PDF (1.1M)</a></li> | <li><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" data-citationid="PMC3162661" class="citationexporter ctxp" role="button" aria-expanded="false" aria-haspopup="true">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3162661%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3162661_files/4047626" alt="Share on Facebook">
                             Facebook
                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3162661%2F&amp;text=Eltrombopag%20increases%20plasma%20rosuvastatin%20exposure%20in%20healthy%20volunteers" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3162661_files/4047627" alt="Share on Twitter">
                             Twitter
                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3162661%2F" role="button" aria-expanded="false" aria-haspopup="true" target="_blank"><img src="./PMC3162661_files/4047628" alt="Share on Google Plus">
                             Google+
                        </a></li></ul></div>
        
        <div id="ajax-portlets" data-pmid="21434975" data-aiid="3162661" data-aid="3162661" data-iid="199617" data-domainid="279" data-domain="brjclinpharm" data-accid="PMC3162661" data-md5="051ac9b28a0b897031d6bc46e4e5851f">
<div class="portlet pubmed_favoritesad">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Save items</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="pmfavad" toggles="ui-portlet_content-25" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-25" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<input type="hidden" name="absid" id="absid" value="3162661"><div id="pubmed_favoritesad" class="empty" data-db="pmc">
<span role="menubar"><div class="ui-ncbisetswitch ltd-hover" role="menuitem" aria-expanded="false" aria-haspopup="true"><a href="http://www.ncbi.nlm.nih.gov/myncbi/collections/" class="jig-ncbisetswitch blind collink ltd-hover ui-ncbisetswitch-hasStar" id="favList" data-jigconfig="destSelector:&#39;#favUL&#39;,starExists:true,createCollectionUrl:&#39;#&#39;,manageCollectionsUrl:&#39;/myncbi/collections/&#39;"><span class="star"></span>Add to Favorites</a><a class="ui-ncbisetswitch-button ltd-hover" title="View more options" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#"><span class="ui-icon ui-icon-triangle-1-s ui-ncbisetswitch-down">View more options</span></a></div></span><div style="display: none; width: 200px; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbilinksmenu ui-ncbisetswitch-popper"><ul id="favUL" class="ui-ncbisetswitch-options"></ul><ul class="ui-ncbisetswitch-actions"><li class="ui-ncbisetswitch-actions-create" style="display: block;"><a class="ui-ncbisetswitch-create-collection" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#">Create collection...</a></li><li class="ui-ncbisetswitch-actions-manage" style="display: block;"><a class="ui-ncbisetswitch-manage-collections" href="http://www.ncbi.nlm.nih.gov/myncbi/collections/">Manage collections...</a></li></ul></div>
</div>
<div class="colloading">loading</div>
<span id="submenu_AddToCollections"><form method="post"><input type="submit" class="button_apply" name="addtocollection" value="1"></form></span>
</div></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" toggles="ui-portlet_content-27" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-27" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/24440960" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.</a><span class="source">[Drug Metab Dispos. 2014]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-29" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, Masuo Y, Horikawa M, Nakamichi N, Ishiwata N, Kato Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Drug Metab Dispos. 2014 Apr; 42(4):726-34. Epub 2014 Jan 17.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/25740267" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.</a><span class="source">[Int J Clin Pharmacol Ther. 2015]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-31" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Kulmatycki K, Hanna I, Meyers D, Salunke A, Movva A, Majumdar T, Natrillo A, Vapurcuyan A, Rebello S, Sunkara G, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Int J Clin Pharmacol Ther. 2015 May; 53(5):345-55. </em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/24375014" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.</a><span class="source">[J Clin Pharmacol. 2014]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-33" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Custodio JM, Wang H, Hao J, Lepist EI, Ray AS, Andrews J, Ling KH, Cheng A, Kearney BP, Ramanathan S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Clin Pharmacol. 2014 Jun; 54(6):649-56. Epub 2014 Jan 17.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/23443754" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.</a><span class="source">[Clin Pharmacol Ther. 2013]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-35" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Tomita Y, Maeda K, Sugiyama Y. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Clin Pharmacol Ther. 2013 Jul; 94(1):37-51. Epub 2012 Nov 7.</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/21884024" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.</a><span class="source">[Cardiovasc Ther. 2012]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-37" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hua WJ, Hua WX, Fang HJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Cardiovasc Ther. 2012 Oct; 30(5):e234-41. Epub 2011 May 25.</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=21434975&amp;log%24=relatedreviews&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Reviews&amp;rendering-type=normal">See reviews...</a><a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=21434975&amp;log%24=relatedarticles&amp;logdbfrom=pmc" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|RelatedArticles&amp;TO=Entrez|Pubmed|Related%20Records&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Cited by other articles in PMC</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-39" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-39" aria-hidden="false">
<ul>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4287283/" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Role of the Breast Cancer Resistance Protein (BCRP/ABCG2) in Drug Transport—an Update</a><span class="source">[The AAPS Journal. 2014]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-41" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mao Q, Unadkat JD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">The AAPS Journal. 2014 Sep 19; 17(1)65-82</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4156548/" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Medication Use and Medical Comorbidity in Patients with Chronic Hepatitis C from a U.S. Commercial Claims Database: High Utilization of Drugs with Interaction Potential</a><span class="source">[European journal of gastroente...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-43" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lauffenburger JC, Mayer CL, Hawke RL, Brouwer KL, Fried MW, Farley JF. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">European journal of gastroenterology &amp; hepatology. 2014 Oct; 26(10)1073-1082</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691435/" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Drug–Drug Interaction Studies: Regulatory Guidance and An Industry Perspective</a><span class="source">[The AAPS Journal. 2013]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-45" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Prueksaritanont T, Chu X, Gibson C, Cui D, Yee KL, Ballard J, Cabalu T, Hochman J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">The AAPS Journal. 2013 Mar 30; 15(3)629-645</em>
</div>
</li>
<li class="brieflinkpopper two_line">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3370749/" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Assessment of the Pharmacokinetic Interaction between Eltrombopag and Lopinavir-Ritonavir in Healthy Adult Subjects</a><span class="source">[Antimicrobial Agents and Chemo...]</span><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-47" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">
<em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Wire MB, McLean HB, Pendry C, Theodore D, Park JW, Peng B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antimicrobial Agents and Chemotherapy. 2012 Jun; 56(6)2846-2851</em>
</div>
</li>
</ul>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/citedby/" ref="reftype=relart&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedByInPmc&amp;TO=PMC|Article|CitedBy&amp;rendering-type=normal">See all...</a>
</div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Links</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="PMCVCitedByPmcArticlesP" toggles="ui-portlet_content-49" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-49" aria-hidden="false"><ul>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pccompound&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pccompound&amp;IdsFromResult=3162661" ref="reftype=Compound&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Compound&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Compound</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-51" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Compound<div class="brieflinkpopdesc">PubChem Compound links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=medgen&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_medgen&amp;IdsFromResult=3162661" ref="reftype=MedGen&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Unknown%20Link%20Name&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">MedGen</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-53" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">MedGen<div class="brieflinkpopdesc">Related information in MedGen</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pubmed/21434975/" ref="reftype=PubMed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|PubMed|Record&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">PubMed</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-55" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">PubMed<div class="brieflinkpopdesc">PubMed citations for these articles</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=pcsubstance&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_pcsubstance&amp;IdsFromResult=3162661" ref="reftype=Substance&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|PubChem%20Substance&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Substance</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-57" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Substance<div class="brieflinkpopdesc">PubChem Substance links</div>
</div>
</li>
<li class="brieflinkpopper">
<a class="brieflinkpopperctrl" href="http://www.ncbi.nlm.nih.gov/pmc/?Db=taxonomy&amp;DbFrom=pmc&amp;Cmd=Link&amp;LinkName=pmc_taxonomy&amp;IdsFromResult=3162661" ref="reftype=Taxonomy&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|DiscoveryLinks&amp;TO=Entrez|Crosslink|Taxonomy&amp;rendering-type=normal" role="button" aria-expanded="false" aria-haspopup="true">Taxonomy</a><div class="brieflinkpop ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" id="ui-brieflinkpop-59" aria-live="assertive" aria-hidden="true" style="top: -100px; left: -100px; display: none;">Taxonomy<div class="brieflinkpopdesc">Related taxonomy entry</div>
</div>
</li>
</ul></div></div>
</div><div class="portlet">
<div class="portlet_head">
<div class="portlet_title"><h3><span>Recent Activity</span></h3></div>
<a name="Shutter" sid="1" href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="portlet_shutter ui-ncbitoggler-open" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" toggles="ui-portlet_content-61" role="button" aria-expanded="true" style="position: absolute; padding: 0px;"></a>
</div>
<div class="ui-helper-reset" aria-live="assertive"><div class="portlet_content ui-ncbitoggler ui-ncbitoggler-slave-open" id="ui-portlet_content-61" aria-hidden="false"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="">
<div class="action">
<a href="javascript:historyDisplayState(&#39;ClearHT&#39;)">Clear</a><a href="javascript:historyDisplayState(&#39;HTOff&#39;)" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState(&#39;HTOn&#39;)" class="HTOff">Turn On</a>
</div>
<ul id="activity">
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c28897fd84438f0ea2202">Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers</a><div class="ralinkpop offscreen_noflow">Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers<div class="brieflinkpopdesc">British Journal of Clinical Pharmacology. 2011 Aug; 72(2)321</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=2" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c28867fd84438f0ea21a8">PMC3162661 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=3" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c2876f2911de5257dada7">Effect of Single-dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Vo...</a><div class="ralinkpop offscreen_noflow">Effect of Single-dose Rifampin on the Pharmacokinetics of Warfarin in Healthy Volunteers<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2010 Oct; 88(4)540</div>
</div>
<div class="tertiary"></div>
</li>
<li class="ra_qry two_line">
<a class="htb" ref="log$=activity&amp;linkpos=4" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c28747fd84438f0ea1ebe">PMC3091944 <span class="number">(1)</span></a><div class="tertiary">PMC</div>
</li>
<li class="ra_rcd ralinkpopper two_line">
<a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=5" href="http://www.ncbi.nlm.nih.gov/portal/utils/pageresolver.fcgi?recordid=576c281bf2911de5257d9e76">Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its ...</a><div class="ralinkpop offscreen_noflow">Accurate Prediction of Dose-Dependent CYP3A4 Inhibition by Itraconazole and Its Metabolites From In Vitro Inhibition Data<div class="brieflinkpopdesc">NIHPA Author Manuscripts. 2010 Oct; 88(4)499</div>
</div>
<div class="tertiary"></div>
</li>
</ul>
<p class="HTOn">Your browsing activity is empty.</p>
<p class="HTOff">Activity recording is turned off.</p>
<p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState(&#39;HTOn&#39;)">Turn recording back on</a></p>
<a class="seemore" href="http://www.ncbi.nlm.nih.gov/sites/myncbi/recentactivity">See more...</a>
</div></div></div>
</div>
<div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p8" name="crb--__p8" rid="__p8" style="position: absolute; visibility: visible; width: 370px; top: 1533px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-63"><ul>
<li class="two_line" reference_id="b1">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19231632/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.</a><span class="one_line_source">[Lancet.  2009]</span><div class="alt-note">
<div class="authors">Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M</div>
<div class="citation">Lancet. 2009 Feb 21; 373(9664):641-8.</div>
</div>
</li>
<li class="two_line" reference_id="b3" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18046027/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.</a><span class="one_line_source">[N Engl J Med.  2007]</span><div class="alt-note">
<div class="authors">McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH, TPL102357 Study Group</div>
<div class="citation">N Engl J Med. 2007 Nov 29; 357(22):2227-36.</div>
</div>
</li>
<li class="two_line" reference_id="b4" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19038790/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.</a><span class="one_line_source">[Stem Cells.  2009]</span><div class="alt-note">
<div class="authors">Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM</div>
<div class="citation">Stem Cells. 2009 Feb; 27(2):424-30.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p9" name="crb--__p9" rid="__p9" style="position: absolute; visibility: visible; width: 370px; top: 1649px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-64"><ul>
<li class="two_line" reference_id="b5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17178259/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.</a><span class="one_line_source">[Clin Pharmacol Ther.  2006]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Niemi M, Backman JT</div>
<div class="citation">Clin Pharmacol Ther. 2006 Dec; 80(6):565-81.</div>
</div>
</li>
<li class="two_line" reference_id="b6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17473846/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  2007]</span><div class="alt-note">
<div class="authors">Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M</div>
<div class="citation">Clin Pharmacol Ther. 2007 Dec; 82(6):726-33.</div>
</div>
</li>
<li class="two_line" reference_id="b7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16198652/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.</a><span class="one_line_source">[Clin Pharmacol Ther.  2005]</span><div class="alt-note">
<div class="authors">Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D</div>
<div class="citation">Clin Pharmacol Ther. 2005 Oct; 78(4):330-41.</div>
</div>
</li>
<li class="two_line" reference_id="b8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16784736/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Role of BCRP 421C&amp;gt;A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.</a><span class="one_line_source">[Clin Chim Acta.  2006]</span><div class="alt-note">
<div class="authors">Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH</div>
<div class="citation">Clin Chim Acta. 2006 Nov; 373(1-2):99-103.</div>
</div>
</li>
<li class="two_line" reference_id="b9">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19474787/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  2009]</span><div class="alt-note">
<div class="authors">Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M</div>
<div class="citation">Clin Pharmacol Ther. 2009 Aug; 86(2):197-203.</div>
</div>
</li>
<li class="two_line" reference_id="b10">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/20130569/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  2010]</span><div class="alt-note">
<div class="authors">Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK</div>
<div class="citation">Clin Pharmacol Ther. 2010 May; 87(5):558-62.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p10" name="crb--__p10" rid="__p10" style="position: absolute; visibility: visible; width: 370px; top: 1954px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-65"><ul>
<li class="two_line" reference_id="b11" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15116058/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  2004]</span><div class="alt-note">
<div class="authors">Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A</div>
<div class="citation">Clin Pharmacol Ther. 2004 May; 75(5):455-63.</div>
</div>
</li>
<li class="two_line" reference_id="b12" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.</a><span class="one_line_source">[Clin Pharmacol Ther.  2004]</span><div class="alt-note">
<div class="authors">Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW</div>
<div class="citation">Clin Pharmacol Ther. 2004 Aug; 76(2):167-77.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/" class="seemore">See links ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p46" name="crb--__p46" rid="__p46" style="position: absolute; visibility: visible; width: 370px; top: 6267px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-66"><ul><li class="two_line" reference_id="b13">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16697742/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.</a><span class="one_line_source">[Gastroenterology.  2006]</span><div class="alt-note">
<div class="authors">Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB</div>
<div class="citation">Gastroenterology. 2006 May; 130(6):1793-806.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p47" name="crb--__p47" rid="__p47" style="position: absolute; visibility: visible; width: 370px; top: 6515px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-67"><ul>
<li class="two_line" reference_id="b7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16198652/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.</a><span class="one_line_source">[Clin Pharmacol Ther.  2005]</span><div class="alt-note">
<div class="authors">Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D</div>
<div class="citation">Clin Pharmacol Ther. 2005 Oct; 78(4):330-41.</div>
</div>
</li>
<li class="two_line" reference_id="b14">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16863454/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.</a><span class="one_line_source">[Expert Opin Drug Metab Toxicol.  2005]</span><div class="alt-note">
<div class="authors">Smith NF, Figg WD, Sparreboom A</div>
<div class="citation">Expert Opin Drug Metab Toxicol. 2005 Oct; 1(3):429-45.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p48" name="crb--__p48" rid="__p48" style="position: absolute; visibility: visible; width: 370px; top: 6757px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-68"><ul>
<li class="two_line" reference_id="b7">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16198652/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.</a><span class="one_line_source">[Clin Pharmacol Ther.  2005]</span><div class="alt-note">
<div class="authors">Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D</div>
<div class="citation">Clin Pharmacol Ther. 2005 Oct; 78(4):330-41.</div>
</div>
</li>
<li class="two_line" reference_id="b8">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16784736/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Role of BCRP 421C&amp;gt;A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.</a><span class="one_line_source">[Clin Chim Acta.  2006]</span><div class="alt-note">
<div class="authors">Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH</div>
<div class="citation">Clin Chim Acta. 2006 Nov; 373(1-2):99-103.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p49" name="crb--__p49" rid="__p49" style="position: absolute; visibility: visible; width: 370px; top: 7062px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-69"><ul><li class="two_line" reference_id="b15">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/18042475/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.</a><span class="one_line_source">[Clin Ther.  2007]</span><div class="alt-note">
<div class="authors">Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q</div>
<div class="citation">Clin Ther. 2007 Oct; 29(10):2194-203.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p50" name="crb--__p50" rid="__p50" style="position: absolute; visibility: visible; width: 370px; top: 7136px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-70"><ul><li class="two_line" reference_id="b13">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16697742/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.</a><span class="one_line_source">[Gastroenterology.  2006]</span><div class="alt-note">
<div class="authors">Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB</div>
<div class="citation">Gastroenterology. 2006 May; 130(6):1793-806.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p51" name="crb--__p51" rid="__p51" style="position: absolute; visibility: visible; width: 370px; top: 7357px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-71"><ul>
<li class="two_line" reference_id="b5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17178259/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.</a><span class="one_line_source">[Clin Pharmacol Ther.  2006]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Niemi M, Backman JT</div>
<div class="citation">Clin Pharmacol Ther. 2006 Dec; 80(6):565-81.</div>
</div>
</li>
<li class="two_line" reference_id="b13">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16697742/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.</a><span class="one_line_source">[Gastroenterology.  2006]</span><div class="alt-note">
<div class="authors">Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB</div>
<div class="citation">Gastroenterology. 2006 May; 130(6):1793-806.</div>
</div>
</li>
<li class="two_line" reference_id="b6">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17473846/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  2007]</span><div class="alt-note">
<div class="authors">Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M</div>
<div class="citation">Clin Pharmacol Ther. 2007 Dec; 82(6):726-33.</div>
</div>
</li>
<li class="two_line" reference_id="b16">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17015053/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  2006]</span><div class="alt-note">
<div class="authors">Niemi M, Pasanen MK, Neuvonen PJ</div>
<div class="citation">Clin Pharmacol Ther. 2006 Oct; 80(4):356-66.</div>
</div>
</li>
<li class="two_line" reference_id="b17">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17108811/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.</a><span class="one_line_source">[Pharmacogenet Genomics.  2006]</span><div class="alt-note">
<div class="authors">Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M</div>
<div class="citation">Pharmacogenet Genomics. 2006 Dec; 16(12):873-9.</div>
</div>
</li>
<li class="two_line" reference_id="b8" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/16784736/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Role of BCRP 421C&amp;gt;A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.</a><span class="one_line_source">[Clin Chim Acta.  2006]</span><div class="alt-note">
<div class="authors">Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH</div>
<div class="citation">Clin Chim Acta. 2006 Nov; 373(1-2):99-103.</div>
</div>
</li>
<li class="two_line" reference_id="b9" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19474787/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.</a><span class="one_line_source">[Clin Pharmacol Ther.  2009]</span><div class="alt-note">
<div class="authors">Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M</div>
<div class="citation">Clin Pharmacol Ther. 2009 Aug; 86(2):197-203.</div>
</div>
</li>
<li class="two_line" reference_id="b18" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/19842935/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Different effects of the ABCG2 c.421C&amp;gt;A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.</a><span class="one_line_source">[Pharmacogenomics.  2009]</span><div class="alt-note">
<div class="authors">Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M</div>
<div class="citation">Pharmacogenomics. 2009 Oct; 10(10):1617-24.</div>
</div>
</li>
<li class="two_line" reference_id="b19" style="display: none;">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17460607/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.</a><span class="one_line_source">[Clin Pharmacol Ther.  2007]</span><div class="alt-note">
<div class="authors">Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y</div>
<div class="citation">Clin Pharmacol Ther. 2007 Nov; 82(5):541-7.</div>
</div>
</li>
</ul><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/" class="seemore">See more ...</a></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p52" name="crb--__p52" rid="__p52" style="position: absolute; visibility: visible; width: 370px; top: 7599px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-72"><ul><li class="two_line" reference_id="b5">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17178259/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal"><span class="invert">Review</span> Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.</a><span class="one_line_source">[Clin Pharmacol Ther.  2006]</span><div class="alt-note">
<div class="authors">Neuvonen PJ, Niemi M, Backman JT</div>
<div class="citation">Clin Pharmacol Ther. 2006 Dec; 80(6):565-81.</div>
</div>
</li></ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p53" name="crb--__p53" rid="__p53" style="position: absolute; visibility: visible; width: 370px; top: 7801px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-73"><ul>
<li class="two_line" reference_id="b20">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/17327409/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.</a><span class="one_line_source">[Blood.  2007]</span><div class="alt-note">
<div class="authors">Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL</div>
<div class="citation">Blood. 2007 Jun 1; 109(11):4739-41.</div>
</div>
</li>
<li class="two_line" reference_id="b22">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/20663993/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.</a><span class="one_line_source">[J Clin Pharmacol.  2011]</span><div class="alt-note">
<div class="authors">Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D</div>
<div class="citation">J Clin Pharmacol. 2011 Jun; 51(6):842-56.</div>
</div>
</li>
</ul></div>
</div>
<div class="portlet brieflink pmc_para_cit" id="crb--__p54" name="crb--__p54" rid="__p54" style="position: absolute; visibility: visible; width: 370px; top: 7959px;">
<div class="portlet_head"></div>
<div class="portlet_content" id="ui-portlet_content-74"><ul><li class="two_line" reference_id="b22">
<a href="http://www.ncbi.nlm.nih.gov/pubmed/20663993/" ref="reftype=pubmed&amp;article-id=3162661&amp;issue-id=199617&amp;journal-id=279&amp;FROM=Article|CitedRefBlock&amp;TO=Entrez|Pubmed|Record&amp;rendering-type=normal">Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.</a><span class="one_line_source">[J Clin Pharmacol.  2011]</span><div class="alt-note">
<div class="authors">Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D</div>
<div class="citation">J Clin Pharmacol. 2011 Jun; 51(6):842-56.</div>
</div>
</li></ul></div>
</div>
</div>   
    </div>
                
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script src="./PMC3162661_files/jquery.scrollTo-1.4.2.js"></script>
<script>
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>



<div id="body-link-poppers"><div id="body-link-popper-b1" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.<div class="authors">Bussel JB, Provan D, Shamsi T, Cheng G, Psaila B, Kovaleva L, Salama A, Jenkins JM, Roychowdhury D, Mayer B, Stone N, Arning M</div><div class="citation">Lancet. 2009 Feb 21; 373(9664):641-8.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19231632/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b1">Ref list</a>]</p></div><div id="body-link-popper-b3" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.<div class="authors">McHutchison JG, Dusheiko G, Shiffman ML, Rodriguez-Torres M, Sigal S, Bourliere M, Berg T, Gordon SC, Campbell FM, Theodore D, Blackman N, Jenkins J, Afdhal NH, TPL102357 Study Group</div><div class="citation">N Engl J Med. 2007 Nov 29; 357(22):2227-36.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18046027/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b3">Ref list</a>]</p></div><div id="body-link-popper-b4" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.<div class="authors">Erickson-Miller CL, Delorme E, Tian SS, Hopson CB, Landis AJ, Valoret EI, Sellers TS, Rosen J, Miller SG, Luengo JI, Duffy KJ, Jenkins JM</div><div class="citation">Stem Cells. 2009 Feb; 27(2):424-30.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19038790/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b4">Ref list</a>]</p></div><div id="body-link-popper-b5" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.<div class="authors">Neuvonen PJ, Niemi M, Backman JT</div><div class="citation">Clin Pharmacol Ther. 2006 Dec; 80(6):565-81.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17178259/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b5">Ref list</a>]</p></div><div id="body-link-popper-b6" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Different effects of SLCO1B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin.<div class="authors">Pasanen MK, Fredrikson H, Neuvonen PJ, Niemi M</div><div class="citation">Clin Pharmacol Ther. 2007 Dec; 82(6):726-33.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17473846/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b6">Ref list</a>]</p></div><div id="body-link-popper-b7" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment.<div class="authors">Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D</div><div class="citation">Clin Pharmacol Ther. 2005 Oct; 78(4):330-41.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16198652/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b7">Ref list</a>]</p></div><div id="body-link-popper-b8" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Role of BCRP 421C&amp;gt;A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males.<div class="authors">Zhang W, Yu BN, He YJ, Fan L, Li Q, Liu ZQ, Wang A, Liu YL, Tan ZR, Fen-Jiang, Huang YF, Zhou HH</div><div class="citation">Clin Chim Acta. 2006 Nov; 373(1-2):99-103.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16784736/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b8">Ref list</a>]</p></div><div id="body-link-popper-b9" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.<div class="authors">Keskitalo JE, Zolk O, Fromm MF, Kurkinen KJ, Neuvonen PJ, Niemi M</div><div class="citation">Clin Pharmacol Ther. 2009 Aug; 86(2):197-203.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19474787/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b9">Ref list</a>]</p></div><div id="body-link-popper-b10" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin.<div class="authors">Tomlinson B, Hu M, Lee VW, Lui SS, Chu TT, Poon EW, Ko GT, Baum L, Tam LS, Li EK</div><div class="citation">Clin Pharmacol Ther. 2010 May; 87(5):558-62.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20130569/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b10">Ref list</a>]</p></div><div id="body-link-popper-b11" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.<div class="authors">Schneck DW, Birmingham BK, Zalikowski JA, Mitchell PD, Wang Y, Martin PD, Lasseter KC, Brown CD, Windass AS, Raza A</div><div class="citation">Clin Pharmacol Ther. 2004 May; 75(5):455-63.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15116058/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b11">Ref list</a>]</p></div><div id="body-link-popper-b12" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine.<div class="authors">Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW</div><div class="citation">Clin Pharmacol Ther. 2004 Aug; 76(2):167-77.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/15289793/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b12">Ref list</a>]</p></div><div id="body-link-popper-b13" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics.<div class="authors">Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, Wang Y, Kim RB</div><div class="citation">Gastroenterology. 2006 May; 130(6):1793-806.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16697742/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b13">Ref list</a>]</p></div><div id="body-link-popper-b14" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true"><span class="invert">Review</span> Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination.<div class="authors">Smith NF, Figg WD, Sparreboom A</div><div class="citation">Expert Opin Drug Metab Toxicol. 2005 Oct; 1(3):429-45.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/16863454/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b14">Ref list</a>]</p></div><div id="body-link-popper-b15" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.<div class="authors">Li Y, Jiang X, Lan K, Zhang R, Li X, Jiang Q</div><div class="citation">Clin Ther. 2007 Oct; 29(10):2194-203.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18042475/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b15">Ref list</a>]</p></div><div id="body-link-popper-b16" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin.<div class="authors">Niemi M, Pasanen MK, Neuvonen PJ</div><div class="citation">Clin Pharmacol Ther. 2006 Oct; 80(4):356-66.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17015053/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b16">Ref list</a>]</p></div><div id="body-link-popper-b17" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.<div class="authors">Pasanen MK, Neuvonen M, Neuvonen PJ, Niemi M</div><div class="citation">Pharmacogenet Genomics. 2006 Dec; 16(12):873-9.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17108811/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b17">Ref list</a>]</p></div><div id="body-link-popper-b18" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Different effects of the ABCG2 c.421C&amp;gt;A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.<div class="authors">Keskitalo JE, Pasanen MK, Neuvonen PJ, Niemi M</div><div class="citation">Pharmacogenomics. 2009 Oct; 10(10):1617-24.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/19842935/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b18">Ref list</a>]</p></div><div id="body-link-popper-b19" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers.<div class="authors">Ieiri I, Suwannakul S, Maeda K, Uchimaru H, Hashimoto K, Kimura M, Fujino H, Hirano M, Kusuhara H, Irie S, Higuchi S, Sugiyama Y</div><div class="citation">Clin Pharmacol Ther. 2007 Nov; 82(5):541-7.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17460607/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b19">Ref list</a>]</p></div><div id="body-link-popper-b20" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Phase 1 clinical study of eltrombopag, an oral, nonpeptide thrombopoietin receptor agonist.<div class="authors">Jenkins JM, Williams D, Deng Y, Uhl J, Kitchen V, Collins D, Erickson-Miller CL</div><div class="citation">Blood. 2007 Jun 1; 109(11):4739-41.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17327409/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b20">Ref list</a>]</p></div><div id="body-link-popper-b22" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.<div class="authors">Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D</div><div class="citation">J Clin Pharmacol. 2011 Jun; 51(6):842-56.</div><p>[<a href="http://www.ncbi.nlm.nih.gov/pubmed/20663993/">PubMed</a>] [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b22">Ref list</a>]</p></div><div id="body-link-popper-b21" class="body-link-popper ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic" style="display: none; width: 30em; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true">21. <span class="element-citation">PROMACTA® (eltrombopag) <span class="ref-journal">Full Prescribing Information.</span> Research Triangle Park, NC: GlaxoSmithKline; 2008. </span> [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#b21">Ref list</a>]</div></div>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <div class="breadcrumbs">You are here: 
            <span id="breadcrumb_text"><a href="http://www.ncbi.nlm.nih.gov/guide/">NCBI</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/guide/literature/">Literature</a> &gt; <a href="http://www.ncbi.nlm.nih.gov/pmc/">PubMed Central (PMC)</a></span></div>
    <a id="help-desk-link" class="help_desk jig-ncbihelpwindow" target="_blank" href="http://www.ncbi.nlm.nih.gov/sites/ehelp?&amp;Ncbi_App=pmc&amp;Db=pmc&amp;Page=literature&amp;Snapshot=/projects/PMC/PMCViewer@4.35&amp;Time=2016-06-23T14:20:57-04:00&amp;Host=ptpmc101">Write to the Help Desk</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="./PMC3162661_files/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="http://www.nlm.nih.gov/" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="http://www.nih.gov/" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="http://www.dhhs.gov/" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="http://www.usa.gov/" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            
            <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html">Copyright</a> | <a href="http://www.ncbi.nlm.nih.gov/About/disclaimer.html#disclaimer">Disclaimer</a> |
            <a href="http://www.nlm.nih.gov/privacy.html" class="newdomain">Privacy</a> | 
            <a href="http://www.ncbi.nlm.nih.gov/guide/browsers/">Browsers</a> | <a href="http://www.nlm.nih.gov/accessibility.html">Accessibility</a> | <a href="http://www.ncbi.nlm.nih.gov/About/glance/contact_info.html">Contact</a>
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="http://www.ncbi.nlm.nih.gov/">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url"><a href="http://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
        </div>
    </div>
    <script type="text/javascript" src="./PMC3162661_files/InstrumentPageStarterJS.js"> </script>    
    <script type="text/javascript" src="./PMC3162661_files/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        <div style="display: none; top: -100px; left: -100px;" aria-live="assertive" aria-hidden="true" class="ui-helper-reset ui-ncbipopper-wrapper ui-ncbipopper-basic">External link. Please review our <a href="http://www.nlm.nih.gov/privacy.html">privacy policy</a>.</div><div class="ui-ncbiautocomplete-holder shadow ui-ncbiautocomplete-holder-clearfix" aria-live="assertive" style="display: none; top: 63.5938px; left: 408.188px; width: 670px; z-index: 1001;"><ul class="ui-ncbiautocomplete-options" role="listbox" aria-activedescendant="term"></ul><div class="ui-ncbiautocomplete-actions shadow" style="display: none;"><a class="ui-ncbiautocomplete-link-pref" style="display: none;">Preferences</a><a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3162661/#" class="ui-ncbiautocomplete-link-off ui-ncbiautocomplete-link-pref-right" style="display: none;">Turn off</a></div></div></div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript>&lt;img alt="statistics" src="/stat?jsdisabled=true&amp;amp;ncbi_db=pmc&amp;amp;ncbi_pdid=article&amp;amp;ncbi_acc=&amp;amp;ncbi_domain=brjclinpharm&amp;amp;ncbi_report=record&amp;amp;ncbi_type=fulltext&amp;amp;ncbi_objectid=&amp;amp;ncbi_pcid=/articles/PMC3162661/&amp;amp;ncbi_app=pmc" /&gt;</noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- F4FC7E8376854741_0014SID /projects/PMC/PMCViewer@4.35 ptpmc101 v4.1.r480124 Mon, Sep 28 2015 02:46:19 -->

<script type="text/javascript" src="./PMC3162661_files/4065628.js" snapshot="pmc"></script>
<div class="ui-dialog ui-widget ui-widget-content ui-corner-all ui-front" tabindex="-1" role="dialog" aria-describedby="epubDialog" aria-labelledby="ui-id-1" style="display: none;"><div class="ui-dialog-titlebar ui-widget-header ui-corner-all ui-helper-clearfix"><span id="ui-id-1" class="ui-dialog-title">Making articles easier to read in PMC</span><button type="button" class="ui-button ui-widget ui-state-default ui-corner-all ui-button-icon-only ui-dialog-titlebar-close" role="button" title="Close"><span class="ui-button-icon-primary ui-icon ui-icon-closethick"></span><span class="ui-button-text">Close</span></button></div><div id="epubDialog" style="display: block;" class="ui-dialog-content ui-widget-content">  <p>We are experimenting with display styles that make it easier to read articles     in PMC.     Our first effort uses eBook readers, which have several "ease of reading"     features already built in.</p>  <p>These PMC articles are best viewed in the <em>iBooks     reader</em>. You may notice problems with the display of certain parts of an article     in other eReaders.</p>  <div class="ui-dialog-buttonpane ui-widget-content ui-helper-clearfix"><button id="cancelEpub" class="ui-state-default ui-corner-all">Cancel</button><button id="downloadEpub" style="float: left" class="ui-state-default ui-corner-all">Download article</button></div>          </div></div><ul class="print-log"><li></li></ul></body></html>